Daily2 天
Icotrokinra shows impressive results in moderate to severe plaque psoriasis in phase 3 trial
Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...
Monthly Prescribing Reference6 天
Icotrokinra Improves Skin Clearance and Cuts Plaque Psoriasis Severity
Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...
Oruka Therapeutics’ Promising Long-Term Strategy and Advancements in Psoriasis Treatments ...
Jefferies analyst Michael Yee has maintained their bullish stance on ORKA stock, giving a Buy rating today.Don't Miss our Black Friday ...